Lymphangioleiomyomatosis

Vascular endothelial growth factor-D (VEGF-D) is the most commonly used biomarker for diagnosing lymphangioleiomyomatosis (LAM). However, lung biopsy is often necessary as well; therefore, defining new biomarkers for LAM is crucial. The aim of this study was to describe the diagnostic accuracy of a...

Descripción completa

Detalles Bibliográficos
Autores: Revilla-López, Eva|||0000-0002-7751-4291, Ruiz de Miguel, Victoria|||0000-0002-9378-9658, López-Meseguer, Manuel|||0000-0003-2650-9238, Berastegui García, Cristina|||0000-0001-9774-9349, Boada Pérez, Meritxell|||0000-0002-8774-8593, Mendoza-Valderrey, Alberto|||0000-0003-4849-1593, Arjona-Peris, Marta|||0000-0002-4997-483X, Zapata-Ortega, Marta, Monforte, Víctor|||0000-0002-2918-7679, Bravo Masgoret, Carles|||0000-0002-9972-867X, Roman, Antonio, Gómez-Ollés, Susana|||0000-0002-8935-7641, Sáez-Giménez, Berta|||0000-0002-9307-728X
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:273240
Acceso en línea:https://ddd.uab.cat/record/273240
https://dx.doi.org/urn:doi:10.3389/fmed.2023.1079317
Access Level:acceso abierto
Palabra clave:Lymphangioleiomyomatosis
Biomarkers
Serum
Metalloproteinases
VEGF-D
Diagnose
Descripción
Sumario:Vascular endothelial growth factor-D (VEGF-D) is the most commonly used biomarker for diagnosing lymphangioleiomyomatosis (LAM). However, lung biopsy is often necessary as well; therefore, defining new biomarkers for LAM is crucial. The aim of this study was to describe the diagnostic accuracy of a variety of biomarkers. We assessed 13 analytes in serum related to extracellular matrix remodeling, lymphatic involvement and angiogenesis in a cohort of patients with LAM, comparing them with patients with other cystic lung diseases (OCLD) and healthy women. A scoring method based on the cut-point of each VEGF-D and metalloproteinase-2 (MMP-2) was used to evaluate the diagnostic performance of the marker combination. A total of 97 subjects were recruited: 59 (61%) LAM patients, 18 (19%) OCLD patients, and 20 (20%) healthy female controls. MMP-2 was the only extracellular matrix remodeling biomarker able to differentiate LAM patients from OCLD and healthy patients. Serum MMP-2 was higher in LAM patients [median 578 (465-832) ng/ml] than in patients with OCLD and healthy controls [medians 360 (314-546) and 427 (365-513) ng/ml, respectively (p < 0.0001)]. The area under ROC curve (AUC) of MMP-2 was 0.785 and that of VEGF-D 0.815 (p = 0.6214). The sensitivity/specificity profiles of each biomarker (54/92% for MMP-2, 59/95% for VEGF-D) yielded a composite score (-6.36 + 0.0059 × VEGF-D + 0.0069 × MMP-2) with higher accuracy than each component alone (AUC 0.88 and sensitivity/specificity 79/87%). Combining MMP-2 and VEGF-D may increase diagnostic accuracy for LAM.

Similares en LA Referencia